Police search Sam Mraiche firm’s HQ in Alberta procurement probe

RCMP executed multiple search warrants Wednesday in an investigation into procurement irregularities involving MHCare, a supplier that has received more than $600 million from Alberta Health Services since 2020, including a $70 million 2022 deal to import children’s medication. The searches escalate legal and reputational risk for MHCare, Alberta Health Services and the provincial government amid parallel Auditor‑General and independent judicial reviews; the auditor expects document review and interviews to be complete by the end of April. The government says it will adopt 18 recommendations and tighten procurement rules (including banning personal email and expanding whistleblower protections), but material contract scrutiny and potential political fallout remain.

Analysis

Escalating governance scrutiny in a large provincial health procurement market will structurally reallocate spend toward large, audited incumbents and compliance vendors. Expect award cadence to slow as procurement thresholds and sign-off layers increase, compressing near-term revenue volatility for small, single-contract suppliers and increasing working-capital stress (we model a 30–60 day increase in payment/award cycle across impacted vendors over 3–9 months).

Second-order winners are established medical distributors, enterprise procurement/GRC software vendors, and consultancies that sell audit-remediation programs; they capture market share not by price but by certifiable controls and capacity to absorb longer lead times. Conversely, high-leverage, PE-backed or single-customer med-supply firms face the largest earnings and default risk because incremental compliance costs and delayed payments (we estimate +1–3% margin headwinds) hit small operators disproportionately.

Near-term catalysts cluster into two windows: a regulatory/oversight report expected within weeks and any criminal/legal developments that could emerge over the next 1–12 months; either can re-rate names with concentrated exposure. The reversal scenario is narrow — rapid exonerations or a decisive, well-communicated procurement reset that restores short-term award flow — but until then capital markets will likely price a premium for transparency and scale.

Key Decisions for Investors

• Long ACN (Accenture) — 9–18 month call spread exposure (buy 9–12 month calls, sell further OTM calls) to capture consulting and procurement tech budget tailwinds; target size 2–4% NAV, risk/reward ~1:3 (limited premium, asymmetric upside if provincial/regional rollouts accelerate).
• Pair trade: Long MCK (McKesson) or CAH (Cardinal Health) equity (6–12 months) / Short a bespoke basket of TSX-listed small-cap medical suppliers with >30% revenue from provincial contracts (3–9 months). Rationale: incumbents gain share and pricing power; shorts face payment and compliance squeezes. Position sizing: 150–200bps net exposure; target 20–35% upside on longs vs 30–50% downside potential on shorts if litigation/contract losses occur.
• Event-driven credit trade: Buy modest protection on Alberta provincial paper (5y CDS or reduce duration/exposure in provincial bond book) into the upcoming oversight report (window: now–end of April). Trade size small (50–100bps portfolio duration equivalent); plausible spread move 10–50bps creates asymmetric payoffs versus limited carry risk.
• Tactical short of leveraged, PE-backed regional suppliers — construct a 3–9 month short basket focusing on firms with concentrated government revenue and weak governance disclosures. Use equity short or long-dated put options where available; risk control: stop-loss at 15% adverse move, target 40–60% gain if contract flow freezes or terms are renegotiated.